Netherlands-based ProFibrix, which has a Seattle subsidiary, announced today it has raised $11 million in Series B funding, led by new investor Gilde Healthcare Partners and including existing investor Index Ventures. ProFibrix was founded in 2004 and makes a dry powder topical tissue sealant that stops bleeding during or after surgery. The product, called Fibrocaps, is currently in a clinical trial in the Netherlands. ProFibrix plans to submit an Investigational New Drug Application to the FDA in the first half of next year.
By posting a comment, you agree to our terms and conditions.